{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:26:51Z","timestamp":1793683611331,"version":"4.5.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journalofnuclearcardiology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.nuclcard.2026.103005","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:57:47Z","timestamp":1792022267000},"page":"103005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease-modifying therapy uptake in transthyretin amyloid cardiomyopathy: A 10-year US analysis across three approved agents"],"prefix":"10.1016","author":[{"given":"Krunal","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-9552","authenticated-orcid":false,"given":"Nisarg","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-2891","authenticated-orcid":false,"given":"David E.","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nuclcard.2026.103005_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly Black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.103005_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.nuclcard.2026.103005_bib3","doi-asserted-by":"crossref","first-page":"102122","DOI":"10.1016\/j.jacadv.2025.102122","article-title":"Early access to tafamidis for patients with transthyretin amyloid cardiomyopathy","volume":"4","author":"Crespo-Leiro","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.nuclcard.2026.103005_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ajhp\/zxag106","article-title":"Treatment of transthyretin amyloid cardiomyopathy with tafamidis 61 mg - real-world data from a tertiary center (TAFA-CRUZ study)","author":"Almeida Carvalho","year":"2026","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.nuclcard.2026.103005_bib5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014Evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ, Cardiovasc Imaging"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358126003867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358126003867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:46:37Z","timestamp":1793681197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358126003867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":5,"alternative-id":["S1071358126003867"],"URL":"https:\/\/doi.org\/10.1016\/j.nuclcard.2026.103005","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying therapy uptake in transthyretin amyloid cardiomyopathy: A 10-year US analysis across three approved agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nuclcard.2026.103005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology.","name":"copyright","label":"Copyright"}],"article-number":"103005"}}